View in EDS HTML Full Text PDF Full Text

Safety, tolerability, pharmacokinetic and pharmacodynamic effects of the muscarinic M1 positive allosteric modulator VU0467319 for Alzheimer's disease: a single ascending-dose study in healthy participants.

Saved in:
Bibliographic Details
Title: Safety, tolerability, pharmacokinetic and pharmacodynamic effects of the muscarinic M1 positive allosteric modulator VU0467319 for Alzheimer's disease: a single ascending-dose study in healthy participants.
Authors: Conley AC; Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, 1601 23rd Ave South, Nashville, TN, 37212, USA., Key AP; Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, 1601 23rd Ave South, Nashville, TN, 37212, USA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA., Blackford JU; Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, 1601 23rd Ave South, Nashville, TN, 37212, USA.; Munroe-Meyer Institute, University of Nebraska Medical Center, Omaha, NE, USA., Russell JK; Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, 1601 23rd Ave South, Nashville, TN, 37212, USA.; Alzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, CA, USA., Albert KM; Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, 1601 23rd Ave South, Nashville, TN, 37212, USA., Gong X; Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, 1601 23rd Ave South, Nashville, TN, 37212, USA., Bubser M; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, USA.; Department of Pharmacology, Vanderbilt University, Nashville, TN, USA., Rook JM; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, USA.; Department of Pharmacology, Vanderbilt University, Nashville, TN, USA., Conn PJ; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, USA.; Department of Pharmacology, Vanderbilt University, Nashville, TN, USA., Lindsley CW; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, USA.; Department of Pharmacology, Vanderbilt University, Nashville, TN, USA., Jones CK; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, USA.; Department of Pharmacology, Vanderbilt University, Nashville, TN, USA., Newhouse PA; Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, 1601 23rd Ave South, Nashville, TN, 37212, USA. paul.newhouse@vanderbilt.edu.
Source: Alzheimer's research & therapy [Alzheimers Res Ther] 2025 Jul 01; Vol. 17 (1), pp. 144. Date of Electronic Publication: 2025 Jul 01.
Publication Type: Journal Article; Clinical Trial, Phase I; Randomized Controlled Trial
Journal Info: Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 101511643 Publication Model: Electronic Cited Medium: Internet ISSN: 1758-9193 (Electronic) NLM ISO Abbreviation: Alzheimers Res Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40598606
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Safety, tolerability, pharmacokinetic and pharmacodynamic effects of the muscarinic M<subscript>1</subscript> positive allosteric modulator VU0467319 for Alzheimer's disease: a single ascending-dose study in healthy participants.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Conley+AC%22">Conley AC</searchLink>; Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, 1601 23rd Ave South, Nashville, TN, 37212, USA.<br /><searchLink fieldCode="AU" term="%22Key+AP%22">Key AP</searchLink>; Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, 1601 23rd Ave South, Nashville, TN, 37212, USA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.<br /><searchLink fieldCode="AU" term="%22Blackford+JU%22">Blackford JU</searchLink>; Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, 1601 23rd Ave South, Nashville, TN, 37212, USA.; Munroe-Meyer Institute, University of Nebraska Medical Center, Omaha, NE, USA.<br /><searchLink fieldCode="AU" term="%22Russell+JK%22">Russell JK</searchLink>; Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, 1601 23rd Ave South, Nashville, TN, 37212, USA.; Alzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, CA, USA.<br /><searchLink fieldCode="AU" term="%22Albert+KM%22">Albert KM</searchLink>; Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, 1601 23rd Ave South, Nashville, TN, 37212, USA.<br /><searchLink fieldCode="AU" term="%22Gong+X%22">Gong X</searchLink>; Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, 1601 23rd Ave South, Nashville, TN, 37212, USA.<br /><searchLink fieldCode="AU" term="%22Bubser+M%22">Bubser M</searchLink>; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, USA.; Department of Pharmacology, Vanderbilt University, Nashville, TN, USA.<br /><searchLink fieldCode="AU" term="%22Rook+JM%22">Rook JM</searchLink>; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, USA.; Department of Pharmacology, Vanderbilt University, Nashville, TN, USA.<br /><searchLink fieldCode="AU" term="%22Conn+PJ%22">Conn PJ</searchLink>; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, USA.; Department of Pharmacology, Vanderbilt University, Nashville, TN, USA.<br /><searchLink fieldCode="AU" term="%22Lindsley+CW%22">Lindsley CW</searchLink>; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, USA.; Department of Pharmacology, Vanderbilt University, Nashville, TN, USA.<br /><searchLink fieldCode="AU" term="%22Jones+CK%22">Jones CK</searchLink>; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, USA.; Department of Pharmacology, Vanderbilt University, Nashville, TN, USA.<br /><searchLink fieldCode="AU" term="%22Newhouse+PA%22">Newhouse PA</searchLink>; Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, 1601 23rd Ave South, Nashville, TN, 37212, USA. paul.newhouse@vanderbilt.edu.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101511643%22">Alzheimer's research & therapy</searchLink> [Alzheimers Res Ther] 2025 Jul 01; Vol. 17 (1), pp. 144. <i>Date of Electronic Publication: </i>2025 Jul 01.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I; Randomized Controlled Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BioMed+Central+Ltd%22">BioMed Central Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101511643 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1758-9193 (Electronic) <i>NLM ISO Abbreviation: </i>Alzheimers Res Ther <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40598606
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1186/s13195-025-01798-4
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 144
    Titles:
      – TitleFull: Safety, tolerability, pharmacokinetic and pharmacodynamic effects of the muscarinic M1 positive allosteric modulator VU0467319 for Alzheimer's disease: a single ascending-dose study in healthy participants.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Conley AC
      – PersonEntity:
          Name:
            NameFull: Key AP
      – PersonEntity:
          Name:
            NameFull: Blackford JU
      – PersonEntity:
          Name:
            NameFull: Russell JK
      – PersonEntity:
          Name:
            NameFull: Albert KM
      – PersonEntity:
          Name:
            NameFull: Gong X
      – PersonEntity:
          Name:
            NameFull: Bubser M
      – PersonEntity:
          Name:
            NameFull: Rook JM
      – PersonEntity:
          Name:
            NameFull: Conn PJ
      – PersonEntity:
          Name:
            NameFull: Lindsley CW
      – PersonEntity:
          Name:
            NameFull: Jones CK
      – PersonEntity:
          Name:
            NameFull: Newhouse PA
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 07
              Text: 2025 Jul 01
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1758-9193
          Numbering:
            – Type: volume
              Value: 17
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Alzheimer's research & therapy
              Type: main
ResultId 1